1.  

Article types	Original article
Language	English
Refereed paper	Refereed
Title	Sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis (XANADU study): an open-label randomised study.
Journal	Formal name：RMD open ISSN code：20565933
Domestic / Foregin	Foregin
Volume, Number, Page	9(2)
Papers・Author	Kubo Satoshi, Miyazaki Yusuke, Amano Koichi, Matsui Kiyoshi, Kameda Hideto, Inoue Yoshino, Nakayamada Shingo, Ogura Takehisa, Kaneko Yuko, Yamaoka Kunihiro, Tanaka Yoshiya.
Publication date	2023/04
Papers・Description	OBJECTIVE: To investigate sustained remission following the discontinuation of tofacitinib in patients with rheumatoid arthritis. METHODS: Patients who had an inadequate response to methotrexate (MTX) with or without biological disease-modifying antirheumatic drugs were randomly divided into two groups at baseline, and tofacitinib treatment in combination with MTX was administered to both groups. Either MTX or tofacitinib was then withdrawn if patients achieved Clinical Disease Activity Index remission at week 52. The primary outcome was the proportion of patients who sustained clinical remission at week 104. RESULTS: A total of 113 patients participated in this study. Among them, a total of 48 patients achieved remission at week 52. After discontinuation of tofacitinib, only 29.2% (7/24) of patients remained remission, while 50.0% (10/20) of patients, which was numerically higher but not statistically significant, sustained remission after MTX discontinuation.